Events Calendar |
|
Northwestern Medicine FASTEST Community Input Session for Stroke Clinical Trial
Date: March 16, 2021
Time: 7:00 PM - 8:00 PM
Sorry, public registration for this event has been closed.
Event Description
Join Harish Shownkeen, MD, interventional neuroradiologist at Northwestern Medicine Central DuPage Hospital, to learn about an upcoming research trial for stroke treatment that could affect you or a loved one.
A type of stroke called intracranial hemorrhage (ICH) accounts for about 10% to 15% of all strokes and has a very high death rate, which has not changed over the past 30 years. Forty percent of people with ICH die within a month; only 20% of patients are able to care for themselves independently after six months.
Usually, patients agree to participate in a research trial only after they learn of the potential risks and benefits of the trial. However, patients who have a hemorrhagic stroke often are unable to discuss proposed treatment, which must be given quickly. The FASTEST research trial, which will study the use of a medication to treat hemorrhagic stroke, has been granted ?Exception From Informed Consent? (EFIC) status by the Food and Drug Administration (FDA).
? This means that the clinical team treating the patient may give the trial medication without consent.
? Before treating the patient, the team must make a reasonable effort to get informed consent from the patient or the patient?s legally authorized representative.
? If no one is able to respond, the trial medication may be given.
Educating our community is an important part of this trial, and it will help you and your loved ones make informed decisions if you are affected by hemorrhagic stroke. Please join us to learn more, provide your feedback and opt out of the trial in advance if you wish.
Whether you are attending or not, you are welcome to please take this online survey (https://redcap.research.cchmc.org/surveys/?s=YALHC7W838)
To learn more about the FASTEST trial: https://nihstrokenet.org/fastest/home
A type of stroke called intracranial hemorrhage (ICH) accounts for about 10% to 15% of all strokes and has a very high death rate, which has not changed over the past 30 years. Forty percent of people with ICH die within a month; only 20% of patients are able to care for themselves independently after six months.
Usually, patients agree to participate in a research trial only after they learn of the potential risks and benefits of the trial. However, patients who have a hemorrhagic stroke often are unable to discuss proposed treatment, which must be given quickly. The FASTEST research trial, which will study the use of a medication to treat hemorrhagic stroke, has been granted ?Exception From Informed Consent? (EFIC) status by the Food and Drug Administration (FDA).
? This means that the clinical team treating the patient may give the trial medication without consent.
? Before treating the patient, the team must make a reasonable effort to get informed consent from the patient or the patient?s legally authorized representative.
? If no one is able to respond, the trial medication may be given.
Educating our community is an important part of this trial, and it will help you and your loved ones make informed decisions if you are affected by hemorrhagic stroke. Please join us to learn more, provide your feedback and opt out of the trial in advance if you wish.
Whether you are attending or not, you are welcome to please take this online survey (https://redcap.research.cchmc.org/surveys/?s=YALHC7W838)
To learn more about the FASTEST trial: https://nihstrokenet.org/fastest/home
